
ESMO 2018: Targeting specific genomic mutation in breast cancer improves outcomes, first study shows
Targeting a common mutation in patients with hormone receptor positive (HR ) HER2 negative (HER2-)…
Targeting a common mutation in patients with hormone receptor positive (HR ) HER2 negative (HER2-)…